HBSP (USA)
-
Carlyle Japan (B)
Godes, David B.; Egawa, Masako; Yamazaki, MayukaCase HBS-508093-EMarketingThis is a supplement to the (A) case. It shows that the networks that the firm had been investing in-- commercial banks--were becoming less and less valuable over time. Given this, Tamotsu Adachi must think about how to go about building a new set of networks.Starting at €5.74
-
Terumo (A)
Godes, David B.; Egawa, Masako; Yamazaki, MayukaCase HBS-508068-EMarketingTo maximize their effectiveness, color cases should be printed in color. Terumo faces two challenges: how to sell its catheter products in the U.S. and its new "Solution Pack" in its domestic market, Japan. The case provides rich detail on the firm's evolution from a manufacturer of thermometers to a seller of commodity products like syringes to a diversified firm offering a range of advanced products-catheters and graphs, for example-in addition...Starting at €8.20
-
Carlyle Japan (A)
Godes, David B.; Egawa, Masako; Yamazaki, MayukaCase HBS-508092-EMarketingTamotsu Adachi, Managing Director of Carlyle Japan, wants to formulate a strategy to improve his firm's ability to source high-quality deals at competitive valuations, or prices. Buyout funds like Carlyle typically have two deal phases: sourcing and monitoring. These correspond to (i) "selling" the benefits to a business owner of going with Carlyle as a buyout partner, and then (ii) increasing the value of that business following the buyout. Sinc...Starting at €8.20
-
Hitachi Rail Limited (B)
Collis, David J.; Kanno, Akiko; Sato, NobuoCase HBS-721365-EStrategyDescribes the strategy and organisation changes made by British executive, Alistair Domer, after he is made head of Hitachi Rail's global business. The company acquires an Italian company, continues to win contracts in the UK, but struggles to bring its gStarting at €5.74
-
Takeda Pharmaceutical Company Limited (B)
Collis, David J.; Sato, Nobuo; Kanno, AkikoCase HBS-721374-EStrategyThis case is a follow up to HBS Case No. 721-373, Takeda Pharmaceutical Company Limited (A). Following the events of the previous case, Takeda reached an agreement to acquire Ireland-based Shire Plc. The case follows some of the achievements and challengeStarting at €5.74
-
Carlyle Japan (C)
Godes, David B.; Egawa, Masako; Yamazaki, MayukaCase HBS-508094-EMarketingThis is a supplement to the (A) and (B) cases. It documents the shift in Carlyle's networking strategy. The firm decreased its focus on building contacts in commercial banking an increased instead the focus on building more contacts with industry directly.Starting at €5.74
-
Hitachi Rail Limited (A)
Collis, David J.; Kanno, Akiko; Sato, NobuoCase HBS-721364-EStrategyHitachi must decide whether to make a British executive, who has successfully built its European rail business from scratch, head of its global rail division even though the bulk of revenues for the unit still come from Japan. The case describes, the histStarting at €8.20
-
Takeda Pharmaceutical Company Limited (A)
Collis, David J.; Sato, Nobuo; Kanno, AkikoCase HBS-721373-EStrategyThis case follows Christophe Weber, President and CEO of Takeda Pharmaceutical Company Limited, a leading pharmaceutical company headquartered in Tokyo, Japan, as Takeda considers acquiring Shire Plc, a biotech company based in Ireland. The acquisition woStarting at €8.20